Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer
- 201 Downloads
We evaluated the changes of health-related quality of life (HRQOL) during the 5 years after radical prostatectomy (RP) or external beam radiation therapy (EBRT) for clinical stage T3 prostate cancer (cT3PC).
Patients and methods
A total of 750 patients who underwent RP (n = 575) or EBRT (n = 175) participated in our longitudinal outcomes study. Of these patients, 48 RP patients (8%) and 63 EBRT patients (36%) presented with cT3PC and were included in this analysis. Patients completed the general and disease-specific HRQOL with the Short Form 36 (SF-36) and University of California, Los Angeles Prostate Cancer Index, respectively.
When examining the mean SF-36 values by time, there was significant impact on treatment outcomes for several items of the general HRQOL in the RP subjects. Those who underwent EBRT reported no significant changes in the general HRQOL throughout the follow-up period. With regard to disease-specific HRQOL, the RP subjects had significantly worse urinary HRQOL post-operatively than the EBRT subjects (P < 0.001). The scores for sexual function declined over the 60 months, but more so in the RP group. The two groups showed similar bowel HRQOL scores throughout the follow-up periods.
Both primary treatments for cT3PC can offer satisfactory functional outcomes from the HRQOL perspective, except for a persistent decrease in the sexual activity score. These results may guide the treatment selection and clinical management of patients with HRQOL impairments after treatment for cT3PC.
KeywordsT3 prostate cancer Quality of life Radical prostatectomy External beam radiation therapy
Androgen deprivation therapy
Analyses of variance
Clinical stage T3 prostate cancer
External beam radiation therapy
Health-related quality of life
Intensity-modulated radiation therapy
RAND 36-Item Short Form
University of California, Los Angeles Prostate Cancer Index
3-dimensional conformal therapy
We thank Emiko Izutsu, Tohoku University Hospital, who assisted in data collection and management.
- 1.Cancer Registration Committee of the Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol, 12, 46–61.Google Scholar
- 12.Walsh, P. C. (2002). Anatomical radical retropubic prostatectomy. In P. C. Walsh, A. B. Retik, A. D. Vaughan, & A. J. Wein (Eds.), Campbell’s urology (8th ed., pp. 3107–3129). Philadelphia: WB Saunders.Google Scholar
- 13.Britton, K. R., Takai, Y., Mitsuya, M., Nemoto, K., Ogawa, Y., & Yamada, S. (2005). Evaluation of inter- and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system. Radiation Medicine, 23, 14–24.PubMedGoogle Scholar
- 22.Zelefsky, M. J., Levin, E. J., Hunt, M., Yamada, Y., Shippy, A. M., Jackson, A., et al. (2008). Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics, 70, 1124–1129.CrossRefPubMedGoogle Scholar
- 23.D’Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004). 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA, 292, 821–827.CrossRefPubMedGoogle Scholar